Biotechnology News and Research

RSS

Omnicare Clinical Research attains Rave Accredited Plus in Medidata’s ASPire to Win program for CRO's

Medidata Solutions, a leading global provider of hosted clinical development solutions, today announced that global contract research organization (CRO) Omnicare Clinical Research has attained Rave Accredited Plus, the most advanced level in Medidata’s ASPire to Win® program for CROs and other service providers.

28 Oct 2009

Quinnova Pharmaceuticals raises $17.4 million through Series B financing

Safeguard Scientifics, Inc., a holding company that builds value in growth-stage life sciences and technology companies, today announced it led a $17.4 million Series B financing round for Quinnova Pharmaceuticals, Inc., with participation from existing investors Thomas, McNerney & Partners and H.I.G. BioVentures.

28 Oct 2009

QB3 collaborates with Mission Bay Capital Fund to provide startup capital for UC scientists

The California Institute of Quantitative Biosciences (QB3) is collaborating with a newly launched $7.5 million fund to provide startup capital for University of California bioscience entrepreneurs and a long-term endowment for QB3.

28 Oct 2009

Auxilium Pharmaceuticals reports increased net revenues of $42.1 million in third quarter 2009

Auxilium Pharmaceuticals, Inc., a specialty biopharmaceutical company, today announced financial results and operational highlights for the quarter ended September 30, 2009. For the third quarter of 2009, Auxilium reported net revenues of $42.1 million compared to net revenues of $32.6 million in the third quarter of 2008.

28 Oct 2009

Treatment with TYSABRI reduces the rate of hospitalization in Crohn’s patients

Elan Corporation, plc and Biogen Idec today announced data showing that treatment with TYSABRI® (natalizumab) significantly reduced the rate of hospitalization compared with placebo in patients with moderate–to–severe Crohn’s disease during both induction and maintenance treatment.

28 Oct 2009

PPD to evaluate FDA's post-market spontaneous adverse event surveillance system

PPD, Inc. today announced it has been awarded a contract by the U.S. Food and Drug Administration (FDA) to evaluate the agency’s Center for Drug Evaluation and Research (CDER) post-market spontaneous adverse event surveillance system. The company will conduct a thorough evaluation of the value of the spontaneous adverse event reports to support safety-related regulatory actions and report its findings to the FDA and the public.

28 Oct 2009

Successful partnership between Mercury Therapeutics and CreaGen Biosciences highlighted

The recent licensing deal between Mercury Therapeutics and Debiopharm showcases the highly successful partnership between Mercury Therapeutics and CreaGen Biosciences, said CreaGen in a statement released today.

28 Oct 2009

European Patent Office to grant patent for R&D Antibodies’ immunoassays and apparatuses

Research & Diagnostic Antibodies LLC (R&D Antibodies) announced today that it has received a notification stating that the European Patent Office intends to grant a patent for its monoclonal antibody-based immunoassays and apparatuses for measuring inducible nitric oxide synthase (iNOS) as a plasma biomarker for the early detection of the sepsis pathology.

28 Oct 2009

Development of VLN cigarettes for use in smoking cessation continues: 22nd Century

22nd Century Limited, LLC is pleased to announce that it is continuing development of a very low nicotine cigarette for use in smoking cessation. Clinical trial results demonstrate that these cigarettes, also referred to as ‘nicotine-free’ and ‘denicotinized,’ may be more effective for quitting than FDA-approved therapies.

28 Oct 2009

IPIT uses Affymetrix’s DMET Plus biomarker panel to expand the PGENI

Affymetrix, Inc. announced today that the Institute for Pharmacogenomics and Individualized Therapy (IPIT) at the University of North Carolina in Chapel Hill is using the company’s DMET™ Plus biomarker panel to expand the Pharmacogenetics for Every Nation Initiative (PGENI).

28 Oct 2009

NCKU transfers microalgal docosahexaenoic acid production technology to Vedan Biotechnology

NCKU President, Academician Michael Ming-Chiao Lai, signed Technology Transfer Agreement in this morning with Mr. Tou-Hsiung Yang, Chairman of Vedan International (Holding) Ltd, witnessed by Vedan Biotechnology President Shih-An (Raymond) Yang and the inventor, Prof. Huey-Lang Yang of the NCKU Institute of Biotechnology.

28 Oct 2009

PPD plans to separate compound partnering business from CRO business; spin-off to result in independent public companies

PPD, Inc. today announced its board of directors has authorized management to proceed with preparations to spin off its compound partnering business from its core contract research organization, or CRO, business.

28 Oct 2009

New biotechnology research center launched by SHRO

The Sbarro Health Research Organization (SHRO), a nonprofit research facility located at Temple University, will dedicate a new state-of-the-art biotechnology research center on Tuesday, October 27th, at 2 p.m. SHRO is one of the top three international laboratories, based on number of publications as ranked by the Cell Cycle Registry,

28 Oct 2009

Scientific breakthrough to derive human parthenogenetic stem cell lines from unfertilized human eggs

International Stem Cell Corporation (OTCBB:ISCO) (www.internationalstemcell.com) and Reproductive Medicine Associates of New York (RMA of New York) have shown that immature, unfertilized human eggs can be used to create “parthenotes” from which human parthenogenetic stem cell lines may be derived. Immature eggs are normally discarded during standard in vitro fertilization (IVF) procedures due to their inability to create an embryo.

28 Oct 2009

Precision Antibody to develop antibodies for NCI's Clinical Proteomic Technologies for Cancer

Precision Antibody(TM) has been selected as the antibody developer for a component of the National Cancer Institute (NCI)'s Clinical Proteomic Technologies for Cancer (CPTC), which is focused on improving the number and standardizing the quality of monoclonal antibody reagents available for clinical cancer proteomics research.

28 Oct 2009

Nabriva Therapeutics closes EUR 15 million financing

Nabriva Therapeutics, a biotechnology company focused on developing a new class of antibiotics for serious infections caused by resistant pathogens, today announced the closing of a EUR 15 Million financing, bringing the total equity funding raised by the company to EUR 57.4 Million (USD 84 Million) since it’s foundation in 2006.

28 Oct 2009

U.S. PTO awards Endocyte patent for vitamin receptor binding anti-cancer agents

Officials at Endocyte Inc., a cancer drug discovery and development company, announced Tuesday (Oct. 27, 2009) that the company has been awarded a patent from the U.S. Patent and Trademark Office covering vitamin receptor binding anti-cancer agents.

28 Oct 2009

Biomagnetics Diagnostics completes negotiations to acquire IBOS technology

Biomagnetics Diagnostics Corp., a developer of revolutionary diagnostic systems and technology for HIV, hepatitis, tuberculosis, and malaria detection, today announced the Company has completed business negotiations with one of the U.S. Government's top national security research institutions regarding the acquisition of rights to the Integrated Optical Biosensor System (IBOS) technology developed by the laboratory personnel. Biomagnetics Diagnostics plans to utilize this technology to enter the significantly underserved market for handheld biosensors capable of detecting a broad range of disease-causing viruses, bacteria and fungi.

28 Oct 2009

Recruitment of Phase II trial of TB-402 completed ahead of schedule

ThromboGenics NV and co-development partner BioInvent International announce that they have completed recruitment of their Phase II trial of TB-402 ahead of schedule.

28 Oct 2009

PPD signs agreement to invest $100 million in Celtic Therapeutics Holdings

PPD, Inc. today announced it has signed an agreement to invest $100 million in Celtic Therapeutics Holdings L.P., an investment partnership organized for the purpose of identifying, acquiring and investing in a diversified portfolio of 10 to 15 novel therapeutic product candidates.

28 Oct 2009

Biotechnology News and Research

Omnicare Clinical Research attains Rave Accredited Plus in Medidata’s ASPire to Win program for CRO's

Quinnova Pharmaceuticals raises $17.4 million through Series B financing

QB3 collaborates with Mission Bay Capital Fund to provide startup capital for UC scientists

Auxilium Pharmaceuticals reports increased net revenues of $42.1 million in third quarter 2009

Treatment with TYSABRI reduces the rate of hospitalization in Crohn’s patients

PPD to evaluate FDA's post-market spontaneous adverse event surveillance system

Successful partnership between Mercury Therapeutics and CreaGen Biosciences highlighted

European Patent Office to grant patent for R&D Antibodies’ immunoassays and apparatuses

Development of VLN cigarettes for use in smoking cessation continues: 22nd Century

IPIT uses Affymetrix’s DMET Plus biomarker panel to expand the PGENI

NCKU transfers microalgal docosahexaenoic acid production technology to Vedan Biotechnology

PPD plans to separate compound partnering business from CRO business; spin-off to result in independent public companies

New biotechnology research center launched by SHRO

Scientific breakthrough to derive human parthenogenetic stem cell lines from unfertilized human eggs

Precision Antibody to develop antibodies for NCI's Clinical Proteomic Technologies for Cancer

Nabriva Therapeutics closes EUR 15 million financing

U.S. PTO awards Endocyte patent for vitamin receptor binding anti-cancer agents

Biomagnetics Diagnostics completes negotiations to acquire IBOS technology

Recruitment of Phase II trial of TB-402 completed ahead of schedule

PPD signs agreement to invest $100 million in Celtic Therapeutics Holdings

Biotechnology eBook

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News